학술논문
Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review.
Document Type
Academic Journal
Author
Locatelli F; Department of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital, Catholic University of the Sacred Heart, Rome, Italy.; Shah B; Moffitt Cancer Center, Tampa, Florida, USA.; Thomas T; Amgen Inc, Thousand Oaks, California, USA.; Velasco K; Amgen Inc, Thousand Oaks, California, USA.; Adedokun B; Amgen Inc, Thousand Oaks, California, USA.; Aldoss I; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.; Gore L; Children's Hospital Colorado and University of Colorado Cancer Center, Colorado, USA.; Hoelzer D; University of Frankfurt, Frankfurt, Germany.; Bassan R; Hematology Unit, Azienda Ulss3 Serenissima, Ospedale dell'Angelo, Venice, Italy.; Park JH; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.; Boissel N; Hematology Adolescent and Young Adult Unit, Saint-Louis Hospital, AP-HP; URP-3518, Institut de Recherche Saint-Louis, Université de Paris, Paris, France.; Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Source
Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE
Subject
Language
English
Abstract
There are inconsistencies in the reporting of CD19 antigen status following treatment with CD19-targeted therapies. A majority of evidence comes from studies reporting small sample sizes. In this review, we systematically summarize published studies that have reported rates of CD19-negative relapse after treatment with either blinatumomab or CD19-directed CAR T-cell therapy and report the rates of CD19-negative relapse when evaluated in a standardized way across trials. CD19-negative relapse appears to occur more commonly in relapses following CAR T-cell therapy compared with blinatumomab, whether proportions are calculated among all treated patients (8.7% vs 4.5%) or among patients who relapse (30% vs 22.5%). The median (range) duration of follow-up was 29.3 (17.4-50.8) and 20.4 (6.9-49.0) months for publications on blinatumomab ( n = 10) and CAR T-cell therapies ( n = 23), respectively. There is a need for standardized reporting of CD19 antigen status in the setting of relapse following novel immunotherapies to inform clinical practice.